1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Single low dose cyclophosphamide: new trials by email Literature Review of Single low dose cyclophosphamide trials Research Report on Single low dose cyclophosphamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population Tecemotide, Single low dose cyclophosphamide, Placebo - Non-Small Cell Lung Cancer | Phase 3 | Terminated | Merck KGaA, Darmstadt, Germany | 285 | 2009-12-01 | 2016-10-26 |
| Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo - Non-small Cell Lung Cancer | Phase 3 | Completed | EMD Serono | 1513 | 2007-01-01 | 2015-11-20 |
Carcinoma, Non-Small-Cell Lung (2)
EMD Serono (1) · Merck KGaA, Darmstadt, Germany (1)
China (2) · Hong Kong (2) · Singapore (2) · South Korea (2) · Taiwan (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1)
PMID 34870327, PMID 21982342, PMID 24331154, PMID 24976972, PMID 25722382